E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Daiichi Sankyo will be responsible for the development, manufacturing and supply of Vanflyta while Innovent Biologics holds sole commercialization rights for Vanflyta in China.
imphoenix82
The Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Trixeo for the maintenance treatment of asthma and Enhertu, in combination with pertuzumab, for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer in the European Union (EU).
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
